Discovery of a Series of Macrocycles as Potent Inhibitors of Leishmania Infantum
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Federico Riu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry - BMC, Uppsala University, 751 23 Uppsala, Sweden. Hauptthemen laut MEDLINE: Leishmania infantum, Antiprotozoal Agents, Macrocyclic Compounds, Plasmodium falciparum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsr?det, Apotekarsocieteten.
Abstract (Originalsprache)
Macrocycles are prominent among drugs for treatment of infectious disease, with many originating from natural products. Herein we report on the discovery of a series of macrocycles structurally related to the natural product hymenocardine. Members of this series were found to inhibit the growth of Plasmodium falciparum, the parasite responsible for most malaria cases, and of four kinetoplastid parasites. Notably, macrocycles more potent than miltefosine, the only oral drug used for the treatment of the neglected tropical disease visceral leishmaniasis, were identified in a phenotypic screen of Leishmania infantum. In vitro profiling highlighted that potent inhibitors had satisfactory cell permeability with a low efflux ratio, indicating their potential for oral administration, but low solubility and metabolic stability. Analysis of predicted crystal structures suggests that optimization should focus on the reduction of π-π crystal packing interactions to reduce the strong crystalline interactions and improve the solubility of the most potent lead.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry - BMC, Uppsala University, 751 23 Uppsala, Sweden.
- Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, 751 24 Uppsala, Sweden.
- Molecular Profiling and Drug Delivery, Research & Development, AbbVie Inc., Worcester, Massachusetts 01605, United States.
- Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
- Molecular Profiling and Drug Delivery, Research & Development, AbbVie Inc, North Chicago, Illinois 60064, United States.
- Drugs for Neglected Diseases initiative (DNDi), 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland.
ORCID-Profile: Larissa Alena Ruppitsch, Richard S Hong, Mohit Tyagi, An Matheeussen, Vasanthanathan Poongavanam, Guy Caljon, Ahmad Y Sheikh, Jan Kihlberg
Förderung
- Vetenskapsr?det
- Apotekarsocieteten
Zitieren
APA
Riu, F., Ruppitsch, L. A., Duy Vo, D., Hong, R. S., Tyagi, M., Matheeussen, A., Hendrickx, S., Poongavanam, V., Caljon, G., Sheikh, A. Y., Sjö, P., & Kihlberg, J. (2024). Discovery of a Series of Macrocycles as Potent Inhibitors of Leishmania Infantum. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01370
Vancouver
Riu F, Ruppitsch LA, Duy Vo D, Hong RS, Tyagi M, Matheeussen A, et al. Discovery of a Series of Macrocycles as Potent Inhibitors of Leishmania Infantum. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01370
BibTeX
@article{Riu2024,
author = {Riu, Federico and Ruppitsch, Larissa Alena and Duy Vo, Duc and Hong, Richard S and Tyagi, Mohit and Matheeussen, An and Hendrickx, Sarah and Poongavanam, Vasanthanathan and Caljon, Guy and Sheikh, Ahmad Y and Sjö, Peter and Kihlberg, Jan},
title = {Discovery of a Series of Macrocycles as Potent Inhibitors of Leishmania Infantum},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01370}
}
EUVIMED